Abundnz has joined the Discovery Analytical Consortium. This is a Consortium of companies to address the need for flexible drug discovery services. The Consortium provides a range of physical chemistry, in vivo efficacy, PK and bioanalytical services supported by experienced study management and consultancy including expert DMPK interpretation. Abundnz further enhances the Consortium by providing services strongly focused on bioanalysis of large molecules.
Abundnz attended MEDICA 2016 as a H2020 SME Instrument Champion.
Abundnz has received a Eurostars grant for a 2-year project called “Comprehensive In Vitro Immune Response Testing (COMPIT)”. Together with UK project partner ImmunoSYS Ltd, we aim to develop a unique in vitro platform for the testing and prediction of the full human immune response to drugs. COMPIT is a system of biological and analytical assays that combines novel cell lines, 3D scaffolds and primary cells to deliver an in vitro human cell-based immune system that recapitulates the in vivo human microenvironment.
Abundnz participates in a STW-OTP grant project called “DEBottlenecking Of Chromatographic Separations (DEBOCS)”. The project aims to improve LC methods and to greatly speed up the development of new methods, based on a combination of high-tech instrumentation and intelligent optimization strategies. Microfluidic chips with nested nanostructures will be efficiently incorporated in state-of-the-art equipment. The hardware and software solutions developed in the DEBOCS project will be tested and implemented in projects to address relevant analytical problems in life sciences. Besides Abundnz, participants are University of Amsterdam, Free University Brussels, Johnson & Johnson, Dow, DSM and Research Institute for Chromatography.
Abundnz will be present at the Mass Spectrometry Advances for Drug Discovery meeting in York (UK).
The meeting is about the use of mass spectrometry (MS) in Innovative Advances in Pre and Early Clinical Drug Discovery.
Abundnz will be present at “Biomedica Life Sciences Summit 2015″ in Genk (Belgium). You can meet us at the innovation market.
On day 2 of the Biomedica summit Abundnz is pitchting during the Pitch Session Breakout.
Next year the summit will be in Aachen, Germany.
Abundnz will participate in the conference “Knowledge for Growth 2015” in Gent (Belgium). “Knowledge for Growth” is Europe’s leading regional life sciences convention.
Knowledge for Growth partnering event
You can meet Abundnz at the partnering event.
You can download the press release about Knowledge for Growth at FlandersBio.
Abundnz is pleased to announce that we have been awarded a prestigious European Union Horizon2020 SME grant. We will be using this grant to further develop a business model for a diagnostic assay in order to continue the growth of our company.
Abundnz and Erasmus Medical Center in Rotterdam (The Netherlands) have received a KIEM grant from the Netherlands Organisation for Scientific Research (NWO). In the project they aim to develop novel methods for the visualisation and quantification of the distribution of a drug in tissues.
In collaboration with our UK partner mmunoSYS, Abundnz will jointly present a seminar on “Novel ultra sensitive assay for bioanalytical and micro dose studies with large molecule drugs” on Wednesday 15 October 2014 at 12-2 pm. Place: Helix 1, Alderley Park Conference Centre, Cheshire. Free access. Please contact us at firstname.lastname@example.org for participation.